[P02BB01, trichlorfon, The risk or severity of adverse effects can be increased when Metrifonate is combined with Pilocarpine.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Pilocarpine.]
[J01GA01, streptomycin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Streptomycin.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Pilocarpine.]
[N06DA01, tacrine, The risk or severity of adverse effects can be increased when Tacrine is combined with Pilocarpine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Pilocarpine.]
[R03CC03, terbutaline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Pilocarpine.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Pilocarpine.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Thiotepa is combined with Pilocarpine.]
[B02AB01, aprotinin, The risk or severity of adverse effects can be increased when Aprotinin is combined with Pilocarpine.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Timolol is combined with Pilocarpine.]
[S01AA12, tobramycin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Tobramycin.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Pilocarpine.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Pilocarpine.]
[S01EB04, demecarium, The risk or severity of adverse effects can be increased when Demecarium is combined with Pilocarpine.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Pilocarpine.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Pilocarpine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Pilocarpine.]
[S01AA05, tyrothricin, The risk or severity of adverse effects can be increased when Tyrothricin is combined with Pilocarpine.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Pilocarpine.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Pilocarpine.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Atenolol is combined with Pilocarpine.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Pilocarpine.]
[L02BB04, enzalutamide, The serum concentration of Enzalutamide can be increased when it is combined with Pilocarpine.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Pilocarpine.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Pilocarpine.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Pilocarpine.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Pilocarpine.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Pilocarpine.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Acebutolol is combined with Pilocarpine.]
[L04AA32, apremilast, The metabolism of Apremilast can be decreased when combined with Pilocarpine.]
[A16AA06, betaine, The risk or severity of adverse effects can be increased when Betaine is combined with Pilocarpine.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Pilocarpine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Pilocarpine.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Pilocarpine.]
[S01AA15, dihydrostreptomycin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Dihydrostreptomycin.]
[S03AA06, gentamicin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Gentamicin.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Pilocarpine.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Pilocarpine.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Pilocarpine.]
[C07AA19, bupranolol, The risk or severity of adverse effects can be increased when Bupranolol is combined with Pilocarpine.]
[N06DA03, rivastigmine, The risk or severity of adverse effects can be increased when Rivastigmine is combined with Pilocarpine.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Pilocarpine.]
[R03CC12, bambuterol, The risk or severity of adverse effects can be increased when Bambuterol is combined with Pilocarpine.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Pilocarpine.]
[C07AA17, bopindolol, The risk or severity of adverse effects can be increased when Bopindolol is combined with Pilocarpine.]
[N01BX04, capsaicin, The risk or severity of adverse effects can be increased when Capsaicin is combined with Pilocarpine.]
[C07AG02, carvedilol, The risk or severity of adverse effects can be increased when Carvedilol is combined with Pilocarpine.]
[J01GB14, plazomicin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Plazomicin.]
[C07AB08, celiprolol, The risk or severity of adverse effects can be increased when Celiprolol is combined with Pilocarpine.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Pilocarpine.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Pilocarpine.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Pilocarpine.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be decreased when combined with Pilocarpine.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Pilocarpine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Pilocarpine.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pilocarpine.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Pilocarpine.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Pilocarpine.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Pilocarpine.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Pilocarpine.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Pilocarpine.]
[N05AH02, clozapine, The metabolism of Clozapine can be decreased when combined with Pilocarpine.]
[J01GB12, arbekacin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Arbekacin.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Pilocarpine.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Pilocarpine.]
[J01XB01, colistin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Colistin.]
[H01AX01, pegvisomant, The risk or severity of adverse effects can be increased when Pegvisomant is combined with Pilocarpine.]
[C07AA14, mepindolol, The risk or severity of adverse effects can be increased when Mepindolol is combined with Pilocarpine.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Pilocarpine.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Pilocarpine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Pilocarpine.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Nebivolol is combined with Pilocarpine.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Pilocarpine.]
[P02CB02, diethylcarbamazine, The risk or severity of adverse effects can be increased when Diethylcarbamazine is combined with Pilocarpine.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Pilocarpine.]
[N07AA03, distigmine, The risk or severity of adverse effects can be increased when Distigmine is combined with Pilocarpine.]
[N01AB08, sevoflurane, The metabolism of Sevoflurane can be decreased when combined with Pilocarpine.]
[V04CX07, edrophonium, The risk or severity of adverse effects can be increased when Edrophonium is combined with Pilocarpine.]
[C07AB13, talinolol, The risk or severity of adverse effects can be increased when Talinolol is combined with Pilocarpine.]
[C07AA16, tertatolol, The risk or severity of adverse effects can be increased when Tertatolol is combined with Pilocarpine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Pilocarpine.]
[N03AG01, valproic acid, The metabolism of Valproic acid can be decreased when combined with Pilocarpine.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Pilocarpine.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Pilocarpine.]
[A02BA04, nizatidine, The risk or severity of adverse effects can be increased when Nizatidine is combined with Pilocarpine.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Pilocarpine.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Pilocarpine.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Pilocarpine.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Pilocarpine.]
[N05CD01, flurazepam, The metabolism of Flurazepam can be decreased when combined with Pilocarpine.]
[S01AA07, framycetin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Framycetin.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Pilocarpine.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Pilocarpine.]
[N06DA04, galantamine, The risk or severity of adverse effects can be increased when Galantamine is combined with Pilocarpine.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Pilocarpine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Pilocarpine.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Pilocarpine.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Pilocarpine.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Pilocarpine.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Pilocarpine.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Pilocarpine.]
[S01EB07, isoflurophate, The risk or severity of adverse effects can be increased when Isoflurophate is combined with Pilocarpine.]
[R03CB01, isoproterenol, The risk or severity of adverse effects can be increased when Isoprenaline is combined with Pilocarpine.]
[S01AA24, kanamycin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Kanamycin.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Pilocarpine.]
[C07AG01, labetalol, The risk or severity of adverse effects can be increased when Labetalol is combined with Pilocarpine.]
[N07AA30, ambenonium, The risk or severity of adverse effects can be increased when Ambenonium is combined with Pilocarpine.]
[S01AA21, amikacin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Amikacin.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Pilocarpine.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Pilocarpine.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Pilocarpine.]
[P01BC02, mefloquine, The risk or severity of adverse effects can be increased when Mefloquine is combined with Pilocarpine.]
[N06DX01, memantine, The risk or severity of adverse effects can be increased when Memantine is combined with Pilocarpine.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Pilocarpine.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Pilocarpine.]
[C07AB02, metoprolol, The risk or severity of adverse effects can be increased when Metoprolol is combined with Pilocarpine.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be decreased when combined with Pilocarpine.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Pilocarpine.]
[C07AA12, nadolol, The risk or severity of adverse effects can be increased when Nadolol is combined with Pilocarpine.]
[L02BG04, letrozole, The metabolism of Letrozole can be decreased when combined with Pilocarpine.]
[S03AA01, neomycin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Neomycin.]
[S01EB06, neostigmine, The risk or severity of adverse effects can be increased when Neostigmine is combined with Pilocarpine.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Pilocarpine.]
[S01AA23, netilmicin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Netilmicin.]
[N07BA01, nicotine, The metabolism of Nicotine can be decreased when combined with Pilocarpine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Pilocarpine.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Pilocarpine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Pilocarpine.]
[J04AB30, capreomycin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Capreomycin.]
[A07AA06, paromomycin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Paromomycin.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Pilocarpine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Pilocarpine.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Pilocarpine.]
[V03AB19, physostigmine, The risk or severity of adverse effects can be increased when Physostigmine is combined with Pilocarpine.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Pilocarpine.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Pilocarpine.]
[C07AB01, practolol, The risk or severity of adverse effects can be increased when Practolol is combined with Pilocarpine.]
[C01BA02, procainamide, The risk or severity of adverse effects can be increased when Procainamide is combined with Pilocarpine.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Pilocarpine.]
[C01BC03, propafenone, The risk or severity of adverse effects can be increased when Propafenone is combined with Pilocarpine.]
[C07AA05, propranolol, The risk or severity of adverse effects can be increased when Propranolol is combined with Pilocarpine.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Pilocarpine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Pilocarpine.]
[N07AA02, pyridostigmine, The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Pilocarpine.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Pilocarpine.]
[J01GB08, sisomicin, The therapeutic efficacy of Pilocarpine can be decreased when used in combination with Sisomicin.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Pilocarpine.]
